Jaguar Health Commences Pivotal Crofelemer Trial for SBS-IF and MVID

Jaguar Health, Inc. has begun dosing the first patient in a trial exploring crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF). This trial is hosted at Sheikh Khalifa Medical City in Abu Dhabi, led by Dr. Mohamad Miqdady. Crofelemer, a plant-based drug, has Orphan Drug Designation from the FDA and European Medicines Agency for both SBS-IF and Microvillus Inclusion Disease (MVID). Early trial results might lead to reimbursed access in European countries by mid-2025.

The trial addresses rare diseases requiring significant medical support such as SBS-IF and MVID. Both conditions entail serious health challenges, including severe diarrhea and malabsorption, making intensive parenteral nutrition necessary. Jaguar CEO Lisa Conte noted the trial as vital for crofelemer's development across various regions including the US and MENA.